The Journal of Organic Chemistry
Article
757, 687 [cm−1]. UV/vis (DCM): λmax = 372, 449; (DMF): λmax
=
Hz) [ppm]. LRMS (ESI) m/z (%): 466 (100) [M − H]−. HRMS
(ESI-TOF) m/z: [M − H]− calcd for C20H10F6N5O2 466.0744;
351, 542 [nm]. The analytical data are in accordance with the
literature values.10
found, 466.0743. IR (ATR): ν = 3069, 2954, 2924, 2854, 1608, 1588,
̃
3-Ethyl-4-((3-ethyl-5-hydroxy-1-phenyl-1H-pyrazol-4-yl)imino)-
1-phenyl-1H-pyrazol-5(4H)-one (1b). According to general proce-
dure B using 50 mg of 0.27 mmol 3-ethyl-1-phenyl-1H-pyrazol-
5(4H)-one (2b), rubazonic acid 1b (45.2 mg, 117 μmol, 88%) was
obtained as a red solid after chromatography (CH/DCM 1:1 →
1588, 1520, 1369, 1151, 969, 870, 759, 728 [cm−1]. UV/vis (DCM):
λmax = 378, 451; (DMF): λmax = 351, 553 [nm].
4-((5-Hydroxy-1,3-diphenyl-1H-pyrazol-4-yl)imino)-1,3-diphen-
yl-1H-pyrazol-5(4H)-one (1g). According to general procedure B
using 100 mg of 0.423 mmol 1,3-diphenyl-1H-pyrazol-5(4H)-one
(2g), rubazonic acid 1g (66.8 mg, 138 μmol, 65%) was obtained as a
red solid after chromatography (DCM). 1H NMR (400 MHz,
CDCl3): δ = 16.99 (s, 1H), 8.09−7.96 (m, 8H), 7.55−7.48 (m, 4H),
7.49−7.38 (m, 2H), 7.39−7.29 (m, 6H) [ppm]. 13C{1H} NMR (101
MHz, CDCl3): δ = 152.6, 152.3, 137.7, 130.6, 129.8, 129.3, 129.2,
128.4, 127.4, 125.9, 121.3 [ppm]. LRMS (ESI) m/z (%): 482 (100)
[M − H]−. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C30H22N5O2,
1
DCM). H NMR (600 MHz, CDCl3): δ = 17.38 (s, 1H), 7.95−7.91
(m, 4H), 7.50−7.41 (m, 4H), 7.33−7.27 (m, 2H), 2.79 (q, J = 7.5 Hz,
4H), 1.36 (t, J = 7.6 Hz, 6H) [ppm]. 13C{1H} NMR (151 MHz,
CDCl3): δ = 158.7, 152.6, 137.8, 129.1, 127.0, 125.3, 121.0, 20.4, 12.2
[ppm]. LRMS (ESI) m/z (%): 388 (100) [M + H]+. HRMS (ESI-
TOF) m/z: [M + H]+ calcd for C22H22N5O2, 388.1768; found,
̃
388.1776. IR (ATR): ν = 3044, 2971, 2925, 2874, 2853, 1731, 1593,
̃
1582, 1492, 1370, 1091, 753, 687, 479 [cm−1]. UV/vis (DCM): λmax
= 375, 452; (DMF): λmax = 351, 540 [nm].
484.1768; found, 484.1766. IR (ATR): ν = 3061, 2955, 2924, 2853,
1564, 1518, 1484, 1456, 1413, 1340, 1307, 961, 754, 689, 668, 493
[cm−1]. UV/vis (DCM): λmax = 382, 464; (DMF): λmax = 363, 574
[nm]. The analytical data are in accordance with the literature
values.10
4-((5-Hydroxy-3-isopropyl-1-phenyl-1H-pyrazol-4-yl)imino)-3-
isopropyl-1-phenyl-1H-pyrazol-5(4H)-one (1c). According to general
procedure B using 50 mg of 0.25 mmol 3-isopropyl-1-phenyl-1H-
pyrazol-5(4H)-one (2c), rubazonic acid 1c (28.8 mg, 69.3 μmol,
56%) was obtained as a red solid after chromatography (CH/DCM
1-(4-Chlorophenyl)-4-((1-(4-chlorophenyl)-5-hydroxy-3-phenyl-
1H-pyrazol-4-yl)imino)-3-phenyl-1H-pyrazol-5(4H)-one (1h). Ac-
cording to general procedure B using 50 mg of 0.19 mmol 1-(4-
chlorophenyl)-3-phenyl-1H-pyrazol-5(4H)-one (2h), rubazonic acid
1h (11.4 mg, 20.6 μmol, 22%) was obtained as a red solid after
1
1:1 → DCM). H NMR (400 MHz, CDCl3): δ = 17.26 (s, 1H),
7.98−7.93 (m, 4H), 7.50−7.43 (m, 4H), 7.35−7.25 (m, 2H), 3.27
(hept, J = 6.9 Hz, 2H), 1.41 (d, J = 7.0 Hz, 12H) [ppm]. 13C{1H}
NMR (101 MHz, CDCl3): δ = 161.6, 152.7, 137.9, 129.1, 126.9,
124.7, 121.0, 27.2, 21.0 [ppm]. LRMS (ESI) m/z (%): 416 (100) [M
+ H]+. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C24H26N5O2,
1
chromatography (CH/DCM 1:1 → CH/DCM 8:2). H NMR (400
MHz, CDCl3): δ = 17.03 (s, 1H), 8.04−7.97 (m, 4H), 7.97−7.89 (m,
4H), 7.49−7.41 (m, 2H), 7.38−7.30 (m, 8H) [ppm]. 13C{1H} NMR
(101 MHz, CDCl3): δ = 152.8, 152.3, 136.3, 132.9, 130.3, 130.0,
129.4, 129.3, 129.0, 128.5, 122.3 [ppm]. LRMS (ESI) m/z (%): 552
(100) [M + H]+. HRMS (ESI-TOF) m/z: [M + H]+ calcd for
̃
416.2081; found, 416.2074. IR (ATR): ν = 3066, 3047, 2968, 2929,
2871, 1525, 1491, 1369, 986, 754, 687 [cm−1]. UV/vis (DCM): λmax
= 375, 455; (DMF): λmax = 351, 541 [nm].
̃
1-(4-Bromophenyl)-4-((1-(4-bromophenyl)-5-hydroxy-3-methyl-
1H-pyrazol-4-yl)imino)-3-methyl-1H-pyrazol-5(4H)-one (1d). Ac-
cording to general procedure B using 50 mg of 0.20 mmol 1-(4-
bromophenyl)-3-methyl-1H-pyrazol-5(4H)-one (2d), rubazonic acid
1d was obtained as a red solid. The insoluble crude product was
washed several times with DCM to afford traces of the pure
compound for analysis. The compound is too insoluble to record
C30H20Cl2N5O2, 552.0989; found, 552.0988. IR (ATR): ν = 2920,
1555, 1516, 1488, 1420, 1338, 960, 856, 754 [cm−1]. UV/vis (DCM):
λmax = 385, 467; (DMF): λmax = 364, 569 [nm].
4-((5-Hydroxy-3-phenyl-1-(p-tolyl)-1H-pyrazol-4-yl)imino)-3-
phenyl-1-(p-tolyl)-1H-pyrazol-5(4H)-one (1i). According to general
procedure B using 50 mg of 0.20 mmol 3-phenyl-1-(p-tolyl)-1H-
pyrazol-5(4H)-one (2i), rubazonic acid 1i (9.5 mg, 19 μmol, 19%)
1
1
13C{1H} NMR. H NMR (400 MHz, CD2Cl2): δ = 17.41 (s, 1H),
was obtained as a red solid after chromatography (DCM). H NMR
(400 MHz, CDCl3): δ = 17.03 (s, 1H), 8.04−7.97 (m, 4H), 7.97−
7.90 (m, 4H), 7.49−7.42 (m, 2H), 7.38−7.31 (m, 8H), 2.44 (s, 6H)
[ppm]. 13C{1H} NMR (101 MHz, CDCl3): δ = 152.4, 152.1, 137.3,
135.3, 130.7, 129.7, 129.3, 128.4, 125.8, 121.3, 115.0, 21.3 [ppm].
LRMS (ESI) m/z (%): 512 (100) [M + H]+. HRMS (ESI-TOF) m/
z: [M + H]+ calcd for C32H26N5O2, 512.2081; found, 512.2078. IR
7.89−7.84 (m, 4H), 7.63−7.56 (m, 4H), 2.35 (s, 6H) [ppm]. LRMS
(ESI) m/z (%): 516 (100) [M − H]−. HRMS (ESI-TOF) m/z: [M +
H]+ calcd for C20H14Br2N5O2, 515.9500; found, 515.9501. IR (ATR):
̃
ν = 3102, 2963, 2922, 1542, 1489, 1375, 1330, 1172, 1006, 820, 480
[cm−1]. UV/vis (DCM): λmax = 375, 452; (DMF): λmax = 351, 540
[nm].
̃
(ATR): ν = 2953, 2920, 2852, 1560, 1508, 1481, 1422, 1341, 1307,
1-(4-Bromophenyl)-4-((1-(4-bromophenyl)-3-butyl-5-hydroxy-
1H-pyrazol-4-yl)imino)-3-butyl-1H-pyrazol-5(4H)-one (1e). Accord-
ing to general procedure B using 500 mg of 1.69 mmol 1-(4-
bromophenyl)-3-butyl-1H-pyrazol-5(4H)-one (2e), rubazonic acid 1e
(265 mg, 440 μmol, 52%) was obtained as a red solid after
1077, 962, 857, 817, 754, 693, 657, 501 [cm−1]. UV/vis (DCM): λmax
= 383, 466; (DMF): λmax = 367, 578 [nm].
4-Imino-3-phenyl-1-(p-tolyl)-1H-pyrazol-5(4H)-one (5i). Accord-
ing to general procedure B using 50 mg of 0.20 mmol 3-phenyl-1-(p-
tolyl)-1H-pyrazol-5(4H)-one (2i), 4-imino-3-phenyl-1-(p-tolyl)-1H-
pyrazol-5(4H)-one (5.3 mg, 20 μmol, 10%) (5i) was obtained as a red
solid after chromatography (DCM). 1H NMR (600 MHz, CDCl3): δ
= 12.07 (s, 1H), 8.39−8.31 (m, 2H), 7.90−7.83 (m, 2H), 7.54−7.47
(m, 3H), 7.33−7.23 (m, 2H), 2.39 (s, 3H) [ppm]. 13C{1H} NMR
(151 MHz, CDCl3): δ = 164.5, 150.7, 147.7, 136.0, 135.0, 131.3,
129.8, 128.9, 128.9, 127.6, 118.6, 21 [ppm]. LRMS (ESI) m/z (%):
264 (100) [M + H]+. HRMS (ESI-TOF) m/z: [M + Na]+ calcd for
1
chromatography (CH/DCM 7:3 → CH/DCM 1:1). H NMR (400
MHz, CDCl3): δ = 17.40 (s, 1H), 7.88−7.81 (m, 4H), 7.58−7.52 (m,
4H), 2.75−2.66 (m, 4H), 1.79−1.67 (m, 4H), 1.46 (h, J = 7.4 Hz,
4H), 0.98 (t, J = 7.3 Hz, 6H) [ppm]. 13C{1H} NMR (101 MHz,
CDCl3): δ = 158.1, 152.4, 136.8, 132.1, 125.4, 122.1, 120.2, 30.3,
26.6, 22.9, 14.0 [ppm]. LRMS (ESI) m/z (%): 600 (100) [M − H]−.
HRMS (ESI-TOF) m/z: [M − H]− calcd for C26H26Br2N5O2,
̃
600.0440; found, 600.0439. IR (ATR): ν = 3109, 2955, 2928, 2870,
̃
2858, 1595, 1573, 1530, 1487, 1351, 1007, 826, 484 [cm−1]. UV/vis
(DCM): λmax = 377, 456; (DMF): λmax = 351, 543 [nm].
C16H13N3NaO, 286.0951; found, 286.0952. IR (ATR): ν = 3196,
3070, 2921, 2857, 1719, 1513, 1328, 1154, 1087, 931, 815, 752
4-((5-Hydroxy-1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-
imino)-1-phenyl-3-(trifluoromethyl)-1H-pyrazol-5(4H)-one (1f). Ac-
cording to general procedure B using 80 mg of 0.34 mmol 1-phenyl-3-
(trifluoromethyl)-1H-pyrazol-5(4H)-one (2f), rubazonic acid 1f (70.2
mg, 150 μmol, 87%) was obtained as a red solid after chromatography
[cm−1].
1-(tert-Butyl)-4-((1-(tert-butyl)-5-hydroxy-3-phenyl-1H-pyrazol-
4-yl)imino)-3-phenyl-1H-pyrazol-5(4H)-one (1j). According to gen-
eral procedure C using 51.3 mg of 0.172 mmol diazidopyrazolone 2j,
rubazonic acid 1j (27.2 mg, 62.3 μmol, 71%) was obtained as a red
1
1
(CH + 1% AcOH → CH/DCM 9:1 + 1% AcOH). H NMR (600
solid after chromatography (CH → CH/DCM 7:3). H NMR (400
MHz, CDCl3): δ = 17.12 (s, 1H), 7.91−7.82 (m, 4H), 7.55−7.47 (m,
4H), 7.45−7.34 (m, 2H) [ppm]. 19F NMR (376 MHz, CDCl3): δ =
−64.79 [ppm]. 13C{1H} NMR (151 MHz, CDCl3): δ = 152.1, 144.6
(q, J = 37.5 Hz), 136.6, 129.4, 128.5, 123.4, 121.5, 119.4 (q, J = 272.3
MHz, CDCl3): δ = 16.35 (s, 1H), 7.94−7.89 (m, 4H), 7.40−7.33 (m,
2H), 7.32−7.23 (m, 4H), 1.70 (s, 18H) [ppm]. 13C{1H} NMR (101
MHz, CDCl3): δ = 153.2, 149.7, 131.5, 129.0, 129.0, 128.2, 125.9,
60.2, 28.4 [ppm]. LRMS (ESI) m/z (%): 444 (100) [M + H]+.
G
J. Org. Chem. XXXX, XXX, XXX−XXX